Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CERT

CERT - Certara, Inc. Stock Price, Fair Value and News

$6.66+0.10 (+1.52%)
Delayed

42/100

CERT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

42/100

CERT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CERT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CERT Price Action

Last 7 days

-5.7%

Last 30 days

-3.9%

Last 90 days

-22.4%

Trailing 12 Months

-36.1%

CERT RSI Chart

CERT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CERT Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-664.49

Price/Sales (Trailing)

2.53

EV/EBITDA

15.13

Price/Free Cashflow

11.21

CERT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CERT Fundamentals

CERT Revenue

Revenue (TTM)

418.8M

Rev. Growth (Yr)

3.28%

Rev. Growth (Qtr)

-0.93%

CERT Earnings

Earnings (TTM)

-1.6M

Earnings Growth (Yr)

-189.63%

Earnings Growth (Qtr)

-486.56%

CERT Profitability

Operating Margin

66.33%

EBT Margin

1.82%

Return on Equity

-0.15%

Return on Assets

-0.1%

Free Cashflow Yield

8.92%

CERT Investor Care

Buy Backs (1Y)

1.17%

Diluted EPS (TTM)

-0.01

CERT Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025394.5M405.8M415.6M418.8M
2024360.7M363.6M372.8M385.1M
2023344.4M352.1M353.0M354.3M
2022300.9M313.6M324.4M335.6M
2021252.8M261.8M275.4M286.1M
2020217.3M226.0M234.8M243.5M
2019000208.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Certara, Inc.

CERT
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEcertara.com
 SECTORHealthcare
 INDUSTRYHealth Information Services
 EMPLOYEES1150

Certara, Inc. Frequently Asked Questions

CERT is the stock ticker symbol of Certara, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Certara, Inc. is 1.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CERT's PE ratio (Price to Earnings) is -664.49 and Price to Sales (PS) ratio is 2.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERT PE ratio will change depending on the future growth rate expectations of investors.